In a double-blind, placebo-controlled, randomized phase III trial (NCT01942135), the palbociclib-fulvestrant treatment led to a longer overall survival (though statistically insignificant) than treatment with placebo-fulvestrant among HR + and HER2 − advanced breast cancer patients who had shown sensitivity to prior endocrine therapy [76]. The gene discussed is HR; the disease is breast carcinoma.